Fate Therapeutics, Inc.
FATE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $150 | $133 | $94 | $194 |
| - Cash | $41 | $41 | $45 | $36 |
| + Debt | $79 | $81 | $83 | $85 |
| Enterprise Value | $189 | $173 | $132 | $244 |
| Revenue | $2 | $2 | $2 | $2 |
| % Growth | -8.7% | 17.1% | -12.4% | – |
| Gross Profit | $2 | $2 | $2 | $2 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$29 | -$31 | -$38 | -$42 |
| % Margin | -1,667% | -1,614.7% | -2,329.5% | -2,268.7% |
| Net Income | -$32 | -$34 | -$38 | -$52 |
| % Margin | -1,852.4% | -1,786.6% | -2,309.5% | -2,803.9% |
| EPS Diluted | -0.27 | -0.29 | -0.32 | -0.44 |
| % Growth | 6.9% | 9.4% | 27.3% | – |
| Operating Cash Flow | -$24 | -$25 | -$34 | -$28 |
| Capital Expenditures | -$2 | -$1 | -$1 | -$0 |
| Free Cash Flow | -$27 | -$26 | -$35 | -$28 |